Clinical Trials Logo

Type II Diabetes Mellitus clinical trials

View clinical trials related to Type II Diabetes Mellitus.

Filter by:

NCT ID: NCT01196728 Completed - Clinical trials for Type II Diabetes Mellitus

Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

Start date: September 2010
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.

NCT ID: NCT01076829 Completed - Clinical trials for Type II Diabetes Mellitus

Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes

Start date: July 2009
Phase: N/A
Study type: Interventional

Polyphenols belong to the largest group of secondary metabolites produced by plants, mainly, in response to biotic or abiotic stresses such as infections, wounding, UV irradiation, exposure to ozone, pollutants, and other hostile environmental conditions. It is thought that the molecular basis for the protective action of polyphenols in plants is their antioxidant and free radical scavenging properties. These numerous phenolic compounds are major biologically active components of spices, aromas, essential oils, and traditional medicines. In order to investigate the impact of spice polyphenols on postprandial flow-mediated dilation, nitric oxide, glucose, insulin, triglycerieds, oxidized LDL, and cytoxic lipid peroxidation products (MDA) levels in men with type 2 diabetes, the investigators propose to achieve the following specific aims using a randomized crossover study design: 1. To determine the effect of a ground beef patty meal with and without polyphenol-rich spices on postprandial levels of plasma oxidized LDL, triglycerides, insulin, glucose, and malondialdehyde (MDA). 2. To determine the effect of a ground beef patty meal with and without polyphenol-rich spices on postprandial levels of nitric oxide and flow-mediated dilation. 3. To determine the effect of a ground beef patty meal with and without a spice blend on MDA accumulation in urine. This study will determine whether spice polyphenols exert a beneficial effect by inhibition of the absorption of lipotoxin MDA in males with type 2 diabetes mellitus.Men with diabetes mellitus type 2 have been selected for this study to enable assessment of markers of vascular health including nitric oxide in plasma and flow-mediated dilation. These findings may help to explain the potentially harmful effects of oxidizable fats found in foods and the important benefit of dietary polyphenols in ameliorating this potentially harmful effect.

NCT ID: NCT01020123 Completed - Clinical trials for Type II Diabetes Mellitus

Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients

NCT ID: NCT00995787 Completed - Clinical trials for Type II Diabetes Mellitus

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Start date: October 2009
Phase: Phase 1
Study type: Interventional

The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.

NCT ID: NCT00960791 Completed - Clinical trials for Type II Diabetes Mellitus

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

ADME
Start date: July 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.

NCT ID: NCT00929539 Completed - Clinical trials for Type II Diabetes Mellitus

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.

NCT ID: NCT00894868 Completed - Clinical trials for Congestive Heart Failure

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Start date: May 2009
Phase: Phase 4
Study type: Interventional

This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.

NCT ID: NCT00887302 Completed - Obesity Clinical Trials

Metabolomics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy

Start date: March 25, 2009
Phase:
Study type: Observational

This study is an investigation of the "metabolomics of RYGB with gastrostomy."

NCT ID: NCT00863954 Completed - Clinical trials for Type II Diabetes Mellitus

Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if using a device called the Resonator, that puts out a very low electromagnetic field, effects blood glucose and A1c levels in people with Type 2 Diabetes.

NCT ID: NCT00561171 Completed - Hypertension Clinical Trials

Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria

Start date: November 2007
Phase: Phase 2
Study type: Interventional

This is a phase II a, double-blind, randomized, parallel-design, four-week study to investigate the efficacy, safety and tolerability of two different doses of SPP635 in type II diabetic patients with mild to moderate hypertension and albuminuria. The total study duration for patients completing the entire study will be approximately 7 weeks including a 2 weeks Screening Phase, 1 week Wash-out Phase, 4 week Treatment Phase and 1 week Follow-up Phase. All treatments other than certain antihypertensive drugs (which are to be washed-out) with an effect on BP and all antidiabetic treatments must be kept at stable dose during the whole study. A maximum of 50 patients in total is planned to be enrolled.